Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Esperion Therapeutics, Inc. (ESPR)

1.6   0.04 (2.56%) 03-24 16:00
Open: 1.54 Pre. Close: 1.56
High: 1.74 Low: 1.52
Volume: 8,100,446 Market Cap: 123(M)

Technical analysis

as of: 2023-03-24 4:25:44 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 5.43     One year: 7.88
Support: Support1: 1.25    Support2: 1.04
Resistance: Resistance1: 4.65    Resistance2: 6.75
Pivot: 3.18
Moving Average: MA(5): 1.53     MA(20): 3.93
MA(100): 6.07     MA(250): 6.3
MACD: MACD(12,26): -1.2     Signal(9): -1
Stochastic oscillator: %K(14,3): 5.6     %D(3): 4.9
RSI: RSI(14): 16.3
52-week: High: 8.86  Low: 1.25
Average Vol(K): 3-Month: 3,733 (K)  10-Days: 11,522 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ESPR ] has closed above bottom band by 24.2%. Bollinger Bands are 212.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.74 - 1.75 1.75 - 1.76
Low: 1.5 - 1.51 1.51 - 1.52
Close: 1.59 - 1.6 1.6 - 1.61

Company Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Headline News

Thu, 23 Mar 2023
Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound? - Yahoo Entertainment

Wed, 22 Mar 2023
2023-03-22 | NDAQ:ESPR | Press Release | Esperion Therapeutics ... - Stockhouse

Mon, 20 Mar 2023
Analyst Rating: Will Esperion Therapeutics Inc (ESPR) Stock Outperform the Market? - InvestorsObserver

Mon, 20 Mar 2023
Q1 2023 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ ... - MarketBeat

Fri, 17 Mar 2023
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus ... - MarketBeat

Fri, 17 Mar 2023
Is Esperion Therapeutics Inc (ESPR) Stock Worth a Buy Friday? - InvestorsObserver

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 77 (M)
Shares Float 66 (M)
% Held by Insiders 0.9 (%)
% Held by Institutions 99.3 (%)
Shares Short 17,250 (K)
Shares Short P.Month 18,850 (K)

Stock Financials

EPS -1.26
EPS Est Next Qtl -1.79
EPS Est This Year -7.29
EPS Est Next Year -5.6
Book Value (p.s.) -4.35
Profit Margin (%) 0
Operating Margin (%) -237.9
Return on Assets (ttm) -35.7
Return on Equity (ttm) 0
Qtrly Rev. Growth 22.2
Gross Profit (p.s.) -0.92
Sales Per Share 0.98
EBITDA (p.s.) -2.34
Qtrly Earnings Growth 0
Operating Cash Flow -175 (M)
Levered Free Cash Flow -136 (M)

Stock Valuations

PE Ratio -1.27
PEG Ratio -0.1
Price to Book value -0.37
Price to Sales 1.62
Price to Cash Flow -0.71

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.